Companies › Aadi Bioscience
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sirolimus FK506-binding protein 1A inhibitor | FKBP1A | Phase 2 | Tumor; Endometrial Cancer; Tumor, Solid | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05103358 | Sirolimus | Phase 2 | Tumor | Oncology | Dec 2024 |
| NCT05661461 | Sirolimus | Phase 1 | Tumor, Solid | Oncology | Aug 2025 |
| NCT05997017 | Sirolimus | Phase 2 | Endometrial Cancer | Oncology | Dec 2026 |
Rapamycin Holdings Mercator MedSystems Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.